Introduction
Epidemiological research has indicated that the prevalence and death rate from arteriosclerosis related cardiovascular disease are slightly elevated in adult epilepsy patients taking antiepileptic drugs (AEDs). 1 According to one pathogenetic hypothesis valproate may contribute to the risk of atherosclerosis: high levels of serum uric acid in patients with valproate may be associated with the development of atherosclerosis. 2 An oxidative stress/antioxidant dysequilibrium 3 and elevated total plasma homocysteine have also been found in patients who had received prolonged treatment with valproate. 4, 5 Valproate may also contribute to atherosclerotic vascular disease by inducing a metabolic syndrome. 6 The prevalence of metabolic syndrome in patients taking valproate is higher than in the general population, especially if valproate is taken for bipolar disorder 7 or epilepsy. 8 However, studies of the effects of valproate in epileptic patients have mostly been of poor design and have yielded conflicting results. 8, 9 The reasons why valproate causes metabolic syndrome in some but not all patients remain unclear and controversial. Genetic factors that influence the several molecular pathways involved in energy homeostasis may offer a possible explanation. Among the fundamental biological effects of the active form of vitamin D, i.e., 1,25(OH)(2)D(3), are the control of calcium and bone metabolism and the regulation of the proliferation and differentiation of many cell types. Vitamin D receptors (VDR) are present in pancreatic beta-cells. 10 Vitamin D may therefore be involved in glucose homeostasis by influencing the regulation of insulin secretion. 11 A previous study has proposed an inverse relationship between vitamin D status and the risk of developing diabetes, insulin resistance (IR), and metabolic syndrome. 12 BsmI polymorphisms are useful genetic markers of bone mineral density (BMD) and the risk of osteoporosis, and have been described in relation to obesity and type 2 diabetes mellitus. 13 VDR is also expressed in adipocytes, and vitamin D could be directly involved in the regulation of adipocyte differentiation and metabolism as well as have an impact on lipoprotein lipase expression.
However, to date only limited data are available about the relationship of BsmI polymorphism and lipid profiles. The aim of this study was to discover whether there is an association between BsmI polymorphisms and lipid abnormalities, glucose homeostasis and metabolic syndrome in patients with epilepsy taking valproate.
Methods
We performed a cross-sectional study to determine the characterization of glucose homeostasis, lipid profile, and metabolic syndrome in adult epilepsy patients. We recruited our patients from the outpatient clinics of Songklanagarind Hospital from May 2011 to May 2012.
The inclusion criteria were: Thai nationals with epilepsy; aged 15-55 years; had received valproate monotherapy for at least 1 year; were seizure free for at least 1 year; had no chronic medical illness other than epilepsy; were taking no medication except valproate; and had a stable body weight over the 6 months prior to inclusion. All subjects performed regular aerobic exercise, at least 30 min three times a week, for at least 3 months before inclusion.
The exclusion criteria were: having significant medical disorders other than epilepsy known to affect lipid or glucose homeostasis; having a significant disability, such as mental retardation, ataxia, paresis, or other motor disability, learning disability, language disorder, hearing or visual disability, psychosis or psychiatric disease; taking medications known to affect lipid or glucose homeostasis, e.g., steroids, glucocorticoids, thiazides, lipid lowering agents, except antiepileptic drugs; or having a family history of diabetes.
All patients completed a questionnaire covering sex, age, age at onset of epilepsy, duration of treatment, occupation and medication. Weight and height were also measured and the body mass index (BMI) was calculated [ 15 The diagnosis of epilepsy was based on clinical data obtained from medical records electroencephalography (EEG) and neuroimaging findings, and, for some specific syndromes, age at onset. Mode of onset was classified as generalized if the patient had generalized seizures and showed generalized epileptiform discharge on the EEG. Focal onset seizures were classified if the subject had a history of focal onset seizures, and either an EEG or a neuroimaging finding which showed a focal abnormality or normal studies. EEGs and neuroimaging were performed on all of the patients. The interictal EEG was abnormal in 47% of patients and normal in 50%. The abnormal EEGs included epileptiform discharge in 66% of patients, generalized slowing of the background activity in 20%, and focal slowing in 14%. The ictal EEG changes were captured in 3% of participants. We classified the etiology as genetic, structural/ metabolic, or unknown. Subjects were classified as genetic if they had a known genetic mutation for their epilepsy, or if they had an epilepsy syndrome which is known to be closely linked to genetic causes. The etiology was defined as unknown in subjects with a normal neurological examination, normal laboratory results (including neuroimaging), and no family history of epilepsy. A structural/metabolic etiology was defined as epilepsy resulting from certain structural abnormalities of the brain, or metabolic conditions. All of the EEGs were interpreted by an EEG certified epileptologist. The MRI findings were confirmed by a neuroradiologist.
The metabolic syndrome was defined as follows, at least three of following criteria had to be met: (1) abdominal obesity, (2) hypertriglyceridemia (at least 150 mg/dl), low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in woman), (3) hypertension (at least 130/85 mmHg), and 4) impaired glucose tolerance. 16 
Laboratory procedures
Laboratory determinations were performed in the morning after a 10-h overnight fasting period. The serum glucose level was determined by the Enzymatic Method of Hexokinase (Modular P800; Roche Diagnostics: Tuttlingen Germany) and the serum insulin level by Electrochemiluminescence immunoassay [ECLIA] (Modular E170; Roche Diagnostics: Mannheim Germany). The sensitivity of the assay was 0.200 mU/L, and the coefficients of variation were 1.38% and 0.87% for intra-assay, and 4.20% and 3.97% for interassay (intra-assay: n = 20, mean = 24.06 mU/L, SD AE 0.33 and mean = 80.05 mU/L, SD AE 0.70; interassay: n = 20, mean = 22.70 mU/L, SD AE 0.95 and mean = 79.26 mU/L, SD AE 3.15). Serum cholesterol level was determined by the CHOD-PAP enzymatic assay method (Modular P800; Roche Diagnostics: Tuttlingen Germany), the triglyceride level was determined by the GPO-PAP enzymatic assay method (Modular P800; Roche Diagnostics: Tuttlingen Germany), the high-density lipoprotein-cholesterol level (HDL-C) was determined using a precipitation procedure with dextran sulfate and magnesium chloride, and the low-density lipoprotein-cholesterol level (LDL-C) was calculated according to the Friedewald formula. Using the fasting glucose and insulin levels, we calculated the homeostasis model assessment (HOMA 17 Using a threshold of !1.73, the patients were classified as having insulin resistance. 18 
Vitamin D receptor
Genomic DNA was isolated from leukocyte nucleids using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Realtime PCR Probe (realtime polymerase chain reaction probe) was performed in a strip tube with a reaction volume of 20 ml, containing 2 ml of SsoFast Probe Supermix ''BioRad'' (Hercules, CA, U.S.A.) (ready to use reactionmix), 0.15 mM of the sense, antisense and probe primers for VDR and 150 ng/ml of genomic DNA. The sequences primer and probe for realtime used PCR were VDR sense 5
0 -TAMRA for wild type and VDR HEX-5 0 ACAGGC-CTGCACATTCCCAAT3 0 -TAMRA for mutation. 19 Realtime PCR Probe amplification to detect for VDR was performed using CFX 96 Connect Realtime-PCR (Bio-Rad Laboratories) with an initial denaturation at 95.0 8C for 2 min, followed by 35 cycles denaturation 95.0 8C for 10 s, annealing 60.0 8C for 30 s, 35 cycles, and final extension at 95.0 8C for 10 s. Analysis Software by CFX manager 2.1 (Life Science Research, Hercules, CA, U.S.A.).
Realtime PCR HRM (realtime polymerase chain reaction high resolution melting) was performed in a strip tube with a reaction volumeof20 ml,containing2 mlofSsoFastEvagreenSupermix''BioRad'' (ready to use reactionmix), 0.15 mMoftheforwardandreverseprimers Aliquots (8 ml) of produced Realtime PCR HRM product were digested with 5 U Bsm I restriction enzymes at 65 8C for 1 h (New England BioLabs, Ipswich, MA, U.S.A.) and detected using 12% polyacrylamide gel electrophoresis run at 120 V for 2 h 30 min. Confirmation was made using sequence ABI 3130 Genetic Analyzer (3130 Collection Software, Life Technologies, Grand Island, NY, USA).
The Ethics Review Committee of the Faculty of Medicine, Prince of Songkla University, approved the study and informed consent was sought and obtained from all patients.
Statistical analysis
The characteristics of the study patients were described in terms of mean and standard deviation for continuous variables, and number and percentage for categorical variables. Comparisons of continuous variables between the two subgroups of subjects were performed using a two-tailed t-test and of categorical variables using the chi-square test. The correlations between fasting blood sugar, fasting insulin, total cholesterol, triglycerides, LDL, HDL, systolic blood pressure, diastolic blood pressure, BMI and duration of treatment with valproate were explored using the Pearson product movement correlation coefficient. P-values of 0.05 were considered statistically significant. Statistical analyses were performed using Stata version 7.0 (Stata Statistical Software: Level 7.0 College Station, TX, USA).
Results
Seventy-five epilepsy patients took part in the study. Fortythree patients had focal onset epilepsy and 32 patients had generalized epilepsy. Of these, the cause of the seizure was regarded as unknown in 36% and structural (remote central nervous system infection and traumatic brain) in 64%. None of the patients had a family history of epilepsy. A majority (85%) were seizure free for more than 24 months.
Basic clinical characteristics, lipid profile, fasting blood glucose level, fasting insulin levels, HOMA, and VDR genotype are shown in Table 1 . In our study, the prevalence of BsmI polymorphism was 22.7%. Overall, the mean age AESD was 32.8 AE 12.3 (range: 15-55) years; 35 were male and 40 female. The mean duration of treatment with epileptic drugs AE SD overall at the time of the study was 25 respectively) . Surprisingly, no correlations between duration of valproate treatment and total triglycerides, total cholesterol, HDL-C and LDL-C, fasting blood glucose and fasting insulin level, or HOMA as well as metabolic syndrome, were detected in either group.
We further compared the individual components of the metabolic syndrome parameters between groups. In the lipid profile, we found that epilepsy patients with BsmI polymorphism had significantly higher total triglycerides, total cholesterol, HDL-C and LDL-C than those with the wild-type VDR gene (161.
0.01, respectively). For glucose homeostasis: fasting blood glucose and fasting insulin level showed no statistically significant difference between epilepsy patients with BsmI polymorphism and those with the wild-type VDR gene (98.0 AE 14.0 vs. 97.4 AE 10.6, p = 0.85, 6.7 AE 1.3 vs. 7.06 AE 1.46, p = 0.37 respectively). Again, we calculated the HOMA and found that HOMA showed no statistically significant difference between epilepsy patients with BsmI polymorphism and those with the wild-type VDR gene (p = 0.11). Insulin resistance was identified in 6 of 17 epilepsy patients with BsmI polymorphism, and 18 of 58 epilepsy patients with the wild-type VDR gene. However, no patient satisfied the criteria of diabetes mellitus in our study. The mean systolic blood pressure (AESD) was higher in patients with BsmI polymorphism (p = 0.02), although there was no statistically significant difference in diastolic blood pressure (p = 0.75). Other variables are shown in Table 1 . BMI of epilepsy patients with BsmI polymorphism was higher than that of patients with the wild-type VDR gene (23.2 AE 3.5 vs. 21.1 AE 3.2 p = 0.02). Ten of the 17 patients with BsmI polymorphism (58.8%) had a high BMI (>23.0) compared with only 13 of the 58 patients with the wild-type VDR gene (22.4%). Metabolic syndrome was present in 11 of the 17 patients with BsmI polymorphism (64.7%) compared with 24 of the 58 patients with the wild-type VDR gene (41.4%). Table 2 shows the prevalence of individual components of metabolic syndrome by sex in epilepsy patients with BsmI polymorphism; no statistical significance between male and female was evident.
Discussion
To our knowledge, this is the first study of the possible role of the BsmI polymorphism in relation to metabolic syndrome in patients with epilepsy taking valproate. The results of this study support the existence of a significant positive association between the presence of BsmI polymorphism and metabolic syndrome in young adults with epilepsy taking valproate. Epilepsy patients who had the BsmI polymorphism had higher total cholesterol, total triglycerides, LDL-C, triglycerides, HDL-C and BMI than patients with the wild-type VDR gene, but no significant differences in fasting blood sugar, fasting insulin level or insulin resistance. In addition, the mean systolic blood pressure was higher in epilepsy patients with the BsmI polymorphism.
Our study provides evidence that epilepsy patients with the BsmI polymorphism are more likely to have metabolic syndrome than epilepsy patients with the wild type. These results are in agreement with other studies. [20] [21] [22] Metabolic syndrome is described as a link between insulin resistance, hypertension, dyslipidemia and type-2 diabetes. Metabolic syndrome is associated with an increased risk of atherosclerotic cardiovascular disease in adults. Recently, conflicting results regarding the association between metabolic syndrome and valproate in epilepsy patients have been reported. 4, 5 The divergent findings may be explained by confounding factors, especially differences between the studies in terms of physical activity, weight change and, most importantly, genetic susceptibility of the participants. We conducted our study on epilepsy patients living in a tropical Asian country who exercise regularly. We found a prevalence of metabolic syndrome of 46.7% overall. The prevalence of metabolic syndrome in epilepsy patients with the BsmI polymorphism was 64.7%, in non-polymorphism carriers it was only 41.4%. In terms of metabolic syndrome components, our study found that epilepsy patients with the BsmI polymorphism had significantly higher total cholesterol, total triglyceride, HDL-C, and LDL-C levels than did patients with the wild type (p = <0.01, 0.01, 0.02, 0.01 respectively). Our findings also demonstrate a greater prevalence of obesity in epilepsy patients with the BsmI polymorphism. These characteristics may indicate that obesity facilitates the development of metabolic syndrome in epilepsy patients with BsmI polymorphism. However, recent studies have demonstrated that metabolic syndrome is more common in obese patients with epilepsy on valproate than in obese people in general. 23, 24 Having said that, not all obese patients taking valproate develop metabolic syndrome. These findings support the concept that the development of metabolic syndrome among obese patients treated with valproate is different from that among the general obese population. Previous reports have found a link between insulin resistance and valproate. 25, 26 Some studies have demonstrated that obese patients on VPA therapy have increased insulin levels with insulin resistance. 26, 27 Most studies have been conducted in Western countries, which differ in terms of food, culture and genetics from Eastern countries. A study of an Asian population did not show any statistically significant difference in insulin resistance between patients taking valproate and patients taking no antiepileptic drug. 28 The factors that cause individual differences remain unclear. Both environmental and genetic factors could contribute to such differences. It is now clear that the vitamin D endocrine system plays an important role in the mechanism regulation of insulin release and the maintenance of glucose tolerance, and can influence insulin sensitivity. 26 The fundamental biological effects of the actions of the active form of vitamin D, especially 1,25 hydroxyvitamin D are exerted on multiple organs. The vitamin D endocrine system regulates cellular differentiation and replication in many target tissues, including the pancreas and adipose tissue; it also regulates blood pressure and volume homeostasis. Variations in this endocrine system can lead to several common chronic diseases and metabolic syndrome. Vitamin D and its analogs exert their actions through the VDR, which is a member of the steroid hormone receptor superfamily. Chromosome 12q12-q13 is the location of the VDR-encoding gene; it comprises 11 exons which together with accompanying introns creates about 75 kb of genomic DNA. 29 BsmI polymorphism occurs in the intron between exons VIII and IX in the 3 0 region of the hVDR. Previous studies have associated the VDR BsmI polymorphism with Type 1 DM. 30 Recently, associations of VDR polymorphism with elevated postprandial insulin levels and type 2 DM have been reported. 31 Ortlepp et al., analyzing the VDR gene and fasting glucose in healthy young men with low physical activity, found that the BsmI polymorphism is associated with altered fasting blood glucose levels, but this effect was absent in gene carriers with high physical activity. 32 An association between BsmI polymorphism and insulin resistance was found in a non-diabetic Caucasian population by Oh et al. 33 They observed that persons with homozygous BsmI polymorphism showed significantly higher levels of HOMA-IR compared with those with heterozygous BsmI polymorphism and the wild type VDR gene, especially after additional adjustment for calcium and vitamin D use. The mechanism is still unclear. However, the possible mechanism of the VDR gene transcription might influence fasting glucose levels by two potentially additive effects of vitamin D in adipocytes and pancreas cells. 34 The effect of vitamin D in the role of insulin secretion may be firstly, 1,25 hydroxyvitamin D directs insulin secretion in the b cell through an increase in intracellular free calcium concentration via a nonselective calcium channel.
35 Table 2 Lipid profile, fasting blood glucose, blood pressure, BMI and individual components of metabolic syndrome by sex in unfavorable VDR polymorphism. 36 In contrast, our study did not show any statistically significant difference in fasting blood glucose levels, fasting insulin levels, or insulin resistance between epilepsy patients with BsmI polymorphism and patients with the wild type VDR gene. This finding is supported by other studies. 37, 38 These data are in conflict, because the findings of an individual study may be affected by confounding factors, such as physical activity, family history, and differences in dietary intake. In our study, we excluded patients with a family history of diabetes, and included only patients who exercised regularly. Our study also demonstrated that the HOMA index is related to metabolic syndrome rather than BMI. Our analysis revealed no association between obesity and insulin resistance or between obesity and fasting blood sugar. Hypertension is one of the important components of metabolic syndrome. Hypertension is associated with low blood levels of ionized and untrafiltrable calcium. 39 Although hypocalcemia may be a causal factor for the development of hypertension, a plausible mechanism for the association of vitamin D deficiency/insufficiency and hypertension is an activation of the renin-angiotensin system (RAS). Inappropriate stimulation of the RAS has been associated with hypertension. Today, there are limited data available to evaluate the effect of VDR gene polymorphisms, especially the BsmI polymorphism, in the regulation of blood pressure in humans. Muray et al.'s study demonstrates the influence of BsmI polymorphism of the VDR gene on blood pressure in healthy men. In the wild type VDR gene, blood pressure levels were clearly lower and, only in them, was vitamin D positively correlated with blood pressure. No influence of the BsmI polymorphism on blood pressure was observed in women. These data reveal that the pathophysiology interaction between vitamin D and sex hormones plays a role in the control of blood pressure. 40 Our study supports the evidence that BsmI polymorphism has a positive correlation with blood pressure. This effect was found in both sexes. There are several limitations to this study. First, it is crosssectional, which limits the investigation of causal relationships. The second limitation of our study is the rather modest sample size. The third limitation is the lack of dietary data; dietary intake was estimated using the recall technique over a short period of time, thus it may not be a good representation of usual or long-term dietary intake. Together, all the methods used to assess self-reported daily dietary intake have several limitations in terms of the accuracy. 41 Finally, there was a lack of normal control subjects. In the futures, we will conduct a study with a larger sample size, compare other antiepileptic drugs, and use normal subjects as the control group.
In summary, the BsmI polymorphism in patients with epilepsy on valproate was associated with a significantly higher prevalence of metabolic syndrome and obesity as well as higher levels of serum level total triglycerides, total cholesterol, LDL-C, HDL-C and systolic blood pressure. This knowledge when weighing up the pros and cons of the use of valproate in individual patients with epilepsy. Genetic markers that help identify individuals at high risk for a particular metabolic effect, which is itself a vascular risk factor for morbidity and mortality, may be useful in guiding treatment decisions, especially in Asian countries.
